Episode 7: A View On Spray-Drying mRNA-based Therapies

A View On Spray-Drying mRNA-based Products Delivering mNRA Therapies: A Bullseye for Asthma and Future Pandemics In this episode, we speak with Carsten Rudolph, CEO and co-founder of Ethris, about a novel spray-dried mRNA therapy designed to restore immune balance in asthma patients and prepare for future pandemics. This episode of A View On takes us deep into the lungs, where science, engineering, and medicine converge. Our guest, Carsten Rudolph, CEO and co-founder of Ethris, explains how his team is developing inhalable mRNA-based therapies for chronic respiratory conditions like asthma, rare diseases such as primary ciliary dyskinesia, and even protection in the case of future COVID-19-like pandemics. Unlike vaccines, which target specific viruses, this approach focuses on strengthening the body’s innate immune response. Ethris’ lead candidate delivers instructions to lung cells to produce a protein that helps the respiratory tract fight off infections. In asthma patients, this immune response is often weakened, so restoring it could help prevent attacks. And since the effect is virus-agnostic, the same therapy could also be used preventively in vulnerable groups during pandemic outbreaks, offering protection before a tailored vaccine is available. It’s a powerful example of how mRNA therapies could move out of the lab and into real-world use, improving chronic care while helping the world prepare for what comes next.